Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Department of the Navy 

# AGENCY:

Department of the Navy, DOD. 

# ACTION:

Notice.

# SUMMARY:

The Department of the Navy hereby gives notice of the general availability of exclusive or partially exclusive licenses under the following pending patent. Any license granted shall comply with 35 U.S.C. 209 and 37 CFR part 404. Applications will be evaluated utilizing the following criteria: (1) Ability to manufacture and market the technology; (2) manufacturing and marketing ability; (3) time required to bring technology to market and production rate; (4) royalties; (5) technical capabilities; and (6) small business status. 

Patent application Serial Number 09/747,521 entitled “Methods for Protection Against Lethal Infection with Bacillus Anthracis” filed 21 December 2000. The present invention relates to the use selected genes from the pathogen Bacillus anthracis for constructing a plasmid or DNA-based vaccine which can be used to immunize susceptible hosts against the pathogenic effects of B. anthracis infection. Moreover, the invention describes the protective effects of immunization with DNA constructs encoding the Protective Antigen (PA) or the Lethal Factor (LF) and mutants thereof. Most importantly, the invention describes the complete protection of hosts following co-immunization of a host with PA and LF demonstrating a surprising synergistic effect. Lastly, the invention teaches the use of the synergistic effect of PA and/or LF genes for use as a general adjuvant for co-immunization with other DNA or protein based vaccines. 

# DATES:

Applications for an exclusive or partially exclusive license may be submitted at any time from the date of this notice. 

# ADDRESSES:

The Office of Technology Transfer, Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910-7500, telephone (301) 319-7428. 

# FOR FURTHER INFORMATION CONTACT:

                        Dr. Charles Schlagel, Director, Office of Technology Transfer, Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910-7500, telephone (301) 319-7428 or E-Mail at                         *schlagelc@nmrc.navy.mil.*

Dated: June 11, 2001. 

J.L. Roth, 

Lieutenant Commander, Judge Advocate General's Corps, U.S. Navy, Federal Register Liaison Officer. 

[FR Doc. 01-15448 Filed 6-19-01; 8:45 am] 

BILLING CODE 3810-FF-P